Compare SWBI & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWBI | DSGN |
|---|---|---|
| Founded | 1852 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 491.2M | 579.9M |
| IPO Year | N/A | 2021 |
| Metric | SWBI | DSGN |
|---|---|---|
| Price | $11.65 | $10.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $11.00 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 559.1K | 298.1K |
| Earning Date | 03-05-2026 | 03-09-2026 |
| Dividend Yield | ★ 4.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $466,396,000.00 | N/A |
| Revenue This Year | $2.62 | N/A |
| Revenue Next Year | $3.23 | N/A |
| P/E Ratio | $55.86 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.73 | $2.60 |
| 52 Week High | $12.05 | $10.97 |
| Indicator | SWBI | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 66.57 | 54.22 |
| Support Level | $11.33 | $9.54 |
| Resistance Level | $12.05 | $10.75 |
| Average True Range (ATR) | 0.39 | 0.69 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 70.47 | 59.69 |
Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.